STK16-IN-1 is an inhibitor of STK16 kinase (IC50: 295 nM).

STK16:295 nM

STK16-IN-1 inhibits mTOR kinase (IC50: 5.56 μM). STK16-IN-1 shows potent inhibitory activity against STK16 kinase (IC50=0.295 μM) with excellent selective across the kinome as assessed using the KinomeScanTM profiling assay. STK16-IN-1 treatment causes a reduction in cell number and accumulation of binucleated cells, which can be recapitulated by RNAi knockdown of STK16 in MCF-7 cells. Co-treatment of STK16-IN-1 with chemotherapeutics such as cisplatin, doxorubicin, colchicine and paclitaxel results in a slight potentiation of the anti-proliferative effects of the chemotherapeutics. STK16-IN-1 provides a useful tool compound for further elucidating the biological functions of STK16) [1].